Host Hotels & Resorts Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Host Hotels & Resorts Inc. Common Stock trades at $22.99 (market cap $15.91B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Host Hotels & Resorts Inc. Common Stock is the larger of the two by market cap, and Host Hotels & Resorts Inc. Common Stock pays a 3.45% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Host Hotels & Resorts Inc. Common Stock for 5 Days and Repligen Corporation Common Stock for 0 Days on average.
| HST | RGEN | |
|---|---|---|
Market Cap | $15.91B | $11.14B |
Volume | 8,053,558 | 1,259,263 |
Sector | Real Estate | Health |
52-Week High | $25.54 | $194.57 |
52-Week Low | $16.02 | $102.87 |
Typical Hold Time | 5 Days | 0 Days |
Enterprise Value | $19.60B | $11.02B |
Dividend Yield | 3.45% | — |
Signals from Pluang's Aura AI — not financial advice
Host Hotels & Resorts (HST) trades at $23.22, up 2.11% on the day, reflecting strong momentum. The stock shows a bullish technical signal with moving averages supporting an uptrend. Fundamentally, the company reported robust earnings, beating estimates in recent quarters, with Q1 2026 EPS of $0.67 significantly exceeding expectations. Revenue for 2025 reached $6.11 billion, and net income margin improved to 16.51% in 2026. Analyst sentiment is positive, with a consensus price target of $25.53, indicating potential upside from current levels.
The outlook for HST is favorable, driven by earnings growth and a solid balance sheet, but risks include economic sensitivity to travel demand and dividend sustainability during downturns. Investment opportunity lies in continued operational strength and valuation appeal, with a P/E of 15.58 below industry averages. Investors should monitor travel sector volatility and interest rate impacts on hotel financing.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Host Hotels & Resorts is a real estate investment trust that owns luxury and upscale hotel properties. Its portfolio includes hotels operated under major global brands.
Read more on HST →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →